Redeye comments on the outcome of Scandion’s rights issue, and we resume our coverage.
Redeye leaves a comment following Initiator Pharma’s announcement of the outcome of the recent prefe...
Q2 report due on Tuesday, 12 July Proved earnings resiliency in Q1, more of the same in Q2 10x ’22e ...
Ludvig Svensson, aktieanalytiker på Erik Penser Bank, presenterar sitt investment case på Calliditas...
Defensive rights issue below NAV… …but strengthens the balance sheet Two largest owners increase the...
Framgångsrik uppgradering av maskinparken Candles annonserade idag att maskinuppgraderingarna i apri...
Redeye leaves a short comment following Initiator Pharma’s announcement earlier today of a minor dir...
This Morning, MGI announced the acquisition of Dataseat, a mobile demand-side platform specializing ...
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends ...
Det avslutande kvartalet kantades av svårigheter som dämpade konsumenternas köpkraft.
Redeye retains its positive view of Formpipe following its deliveries deal with Malmö Stad.
Q2 report due on 15 July We cut Q2’22 sales and EBIT The share is trading at 9x-4x EV/EBIT in ‘22e-...
Redeye is encouraged by Enviro’s latest regulatory progress – attaining an environmental permit for ...
Recyctec tillkännagav den 30:e juni att bolaget inlett ett samarbete under vilket Comfortkedjans med...
Yesterday evening, Nitro Games announced that it received a follow-up B2B order from an existing US-...
Avslutar 2021/22 med tillväxt Omsättningen för Q4 uppgick till 17,3 mkr (16 mkr) motsvarande en till...
CirChem har meddelat att Mark- och miljödomstolen i Vänersborg har beviljat bolaget tillstånd för ut...
Redeye leaves its comments on Pila Pharma following today’s uplifting news that the three-month prec...
Redeye embraces the news regarding the OECD validation on GARDskin.
Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 ...
